BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18971124)

  • 1. Acromegaly, growth hormone and cancer risk.
    Renehan AG; Brennan BM
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):639-57. PubMed ID: 18971124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does growth hormone cause cancer?
    Jenkins PJ; Mukherjee A; Shalet SM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):115-21. PubMed ID: 16430706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications.
    Renehan AG; O'Connell J; O'Halloran D; Shanahan F; Potten CS; O'Dwyer ST; Shalet SM
    Horm Metab Res; 2003; 35(11-12):712-25. PubMed ID: 14710350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in the risk of neoplasia in GH deficiency.
    Pekic S; Stojanovic M; Popovic V
    Best Pract Res Clin Endocrinol Metab; 2017 Feb; 31(1):35-47. PubMed ID: 28477731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the GH-IGF axis play a role in cancer pathogenesis?
    Cohen P; Clemmons DR; Rosenfeld RG
    Growth Horm IGF Res; 2000 Dec; 10(6):297-305. PubMed ID: 11161960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GH-IGF-I axis and the cardiovascular system: clinical implications.
    Colao A
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The critical parameters in GH excess.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(5 Suppl):92-5. PubMed ID: 16114283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of differentiated thyroid carcinoma in acromegaly.
    Tita P; Ambrosio MR; Scollo C; Carta A; Gangemi P; Bondanelli M; Vigneri R; degli Uberti EC; Pezzino V
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):161-7. PubMed ID: 16060909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acromegaly induced by growth hormone replacement therapy.
    Karges B; Pfäffle R; Boehm BO; Karges W
    Horm Res; 2004; 61(4):165-9. PubMed ID: 14707471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice.
    Bielohuby M; Roemmler J; Manolopoulou J; Johnsen I; Sawitzky M; Schopohl J; Reincke M; Wolf E; Hoeflich A; Bidlingmaier M
    Exp Biol Med (Maywood); 2009 Aug; 234(8):1002-9. PubMed ID: 19491373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for the syndromes of GH excess.
    Arosio M; Cannavò S; Epaminonda P; Ronchi C; Chiodini I; Adda G
    J Endocrinol Invest; 2003; 26(10 Suppl):36-43. PubMed ID: 15497658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
    Wiesli P; Zwimpfer C; Zapf J; Schmid C
    Acta Obstet Gynecol Scand; 2006; 85(8):900-5. PubMed ID: 16862465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M
    Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acromegaly and cancer.
    Jenkins PJ
    Horm Res; 2004; 62 Suppl 1():108-15. PubMed ID: 15761242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neoplastic complications of acromegaly.
    Terzolo M; Daffara F; Reimondo G; Allasino B; Ventura M; Angeli A
    J Endocrinol Invest; 2003; 26(8 Suppl):32-4. PubMed ID: 15233209
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancers associated with acromegaly.
    Jenkins PJ
    Neuroendocrinology; 2006; 83(3-4):218-23. PubMed ID: 17047386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine levels in acromegaly patients.
    Hekimsoy Z; Ozmen B; Ulusoy S
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.